Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
EV

NASDAQ · EVAX

Evaxion Biotech A/S

Healthcare · Biotechnology

$2.97

Up+$0.01 (+0.34%)

Updated Nov 5, 2026, 3:30 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
40.36M
P/E ratio
-11.8
Dividend yield
0.00%
52-week range
$2.72 – $4.75
Volume
27.62K
Avg. volume
1.63M

Price performance · EVAX

EVAX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

EVAX closed at $2.97 after 21 trading sessions, down 6.01% for the selected period.

Last close
$2.97
Period change
-6.01%
Period low
$2.76
Period high
$4.05
Daily close
View OHLC price history
EVAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$3.05$3.16$2.97$2.9727.62K
Nov 3, 2026$3.19$3.19$2.93$2.9628.87K
Nov 2, 2026$2.93$3.095$2.90$2.9234.98K
Oct 30, 2026$3.11$3.155$2.89$2.9346.2K
Oct 29, 2026$3.10$3.17$3.00$3.0841.31K
Oct 28, 2026$3.01$3.19$3.01$3.1151.16K
Oct 27, 2026$3.09$3.2352$2.93$3.0475.75K
Oct 26, 2026$3.78$3.78$2.95$3.08220.55K
Oct 23, 2026$3.96$4.00$3.65$3.76161.91K
Oct 22, 2026$3.73$3.75$3.55$3.71107.93K
Oct 21, 2026$4.16$4.50$3.65$3.71326.11K
Oct 20, 2026$3.30$4.1171$3.22$4.05535.36K
Oct 19, 2026$3.11$3.60$2.972$3.33469.66K
Oct 16, 2026$2.85$2.9191$2.79$2.8378.13K
Oct 15, 2026$2.80$2.90$2.79$2.8035.11K
Oct 14, 2026$2.76$2.83$2.7531$2.8050.4K
Oct 13, 2026$2.98$2.99$2.72$2.76134.06K
Oct 12, 2026$3.07$3.23$2.99$3.0060.82K
Oct 9, 2026$3.03$3.13$3.02$3.0727.86K
Oct 8, 2026$3.18$3.23$3.02$3.0563.97K
Oct 7, 2026$3.16$3.25$3.11$3.1621.75K

Latest EVAX news

The latest Smart Investors Daily articles mentioning EVAX.

Stock researchCompany · Overview

EVAX research

Overview

Company profile and research snapshot.

Company profile

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.50
Implied upside
—
Analysts
—
EVAX recent ratings
DateFirmRatingTarget
Apr 24, 2026HC Wainwright & Co.Buy—
Mar 10, 2026Jones TradingBuy—
Mar 9, 2026Lake StreetBuy—
Mar 9, 2026HC Wainwright & Co.Buy—
Oct 30, 2025Edward JonesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology™ as best digital health solution. It is the first time the prestigi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By